In this episode, we sat down with Stuart Long (https://www.linkedin.com/in/stuartelong/), CEO of InfoBionic (https://infobionic.ai/). InfoBionic's virtual cardiac telemetry platform, MoMe ARC®, brings together a tiered hospital-grade monitoring cap...
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
[upbeat music] I heard a doctor say once, "I can't swing a dead cat and not hit 10 cardiac reps in my office." So it's a really crowded space, so how do you rise above and get attention, right? And so when you don't have a product problem, but you have a channel problem, you have to diversify. You gotta really think about how can you be where the customer's making a decision. Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.
Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. Hey, everyone, it's Scott. In this episode of MedSider, I sat down with Stuart Long, CEO of Infobionic. He's held the role since March of 2017, bringing more than two decades of experience in the medical device and health technology sectors. Stuart's previous leadership roles included CEO of Monarch Medical Systems, Global Chief Marketing and Sales Officer at Capsule Tech, which sold to Qualcomm Life, and executive positions at Philips Healthcare, Fujifilm, and others.
Here are a few of the key things that we discussed in this conversation. First, maximize funding efficiency through creative capital strategies that prioritize non-dilutive options. Stuart's approach combines venture debt with equity financing and treating equity as prime real estate to be carefully preserved. He emphasizes finding investors willing to fight the good fight during challenging periods, noting that favorable terms mean nothing if investors abandon you when difficulties arise. Second, win in crowded markets with a multi-pronged sales approach. Leveraging diverse channels from direct reps to independent partners and strategic distributors helps startups build trust, gain traction, and maintain optionality where traditional methods fall short.
Third, structure your startup for premium valuations by combining growth with strategic adjacencies. Stuart's formula focuses on achieving year-over-year revenue growth of 30% to 50% while simultaneously developing products that open new addressable markets for strategic acquirers, transforming strong financial performance into premium valuations through strategic portfolio development. All right, before we dive into this episode, I'm pumped to share that volume seven of MedSider Mentors is now live. This latest edition highlights key takeaways from recent MedSider interviews with incredible entrepreneurs like Bill Hunter, CEO of Canary Medical, Brian Lord, CEO of Pristine Surgical, Don Crawford, co-founder of Saphion and current CEO of Corvista Health, and other proven med tech founders and CEOs.
Look, we get it. Keeping up with every MedSider interview isn't easy. That's why we created MedSider Mentors. These e-book volumes distill the best practices and insider secrets from top founders and CEOs, all in a downloadable, easy-to-digest format. To check the latest volume out, head over to medsiderradio.com/mentors. Premium members get free access to all past and future volumes, plus a treasure trove of other resources. If you're not a premium member yet, you should definitely consider signing up. We recently revamped MedSider with swanky new features, especially for our premium members. In addition to every volume of MedSider Mentors, you'll get full access to our entire interview library dating back to 2010.
You'll also get MedSider Playbooks, curated guides packed with actionable insights on topics like fundraising, regulatory challenges, reimbursement strategies, and more. And if you're fundraising, don't miss our exclusive investor database featuring over 750 life science VCs, family offices, and angels. We've even created three custom packages to help you with your next fundraise. Learn more about MedSider Mentors and our premium memberships by visiting medsiderradio.com/mentors. All right, without further ado, let's dive into the interview. [upbeat music] All right, Stuart, welcome to MedSider Radio. Appreciate you coming on. Oh, great to be here. Thanks for having me.
The folks are largely listening to this, but I'm looking at, uh, your video, and you've got a great, uh, great picture in the background. I love it. [laughs] I took that picture, by the way. Yeah. Oh, did you? Both of them. Yeah, yeah. Awesome. Awesome. Yeah. Yeah. One of my, one of my business partners is Brady Hatcher, and, like, throughout his whole facility, it's, like, artwork that's kind of similar to this, but he took it all, right? Yeah. So it's kinda, kinda cool. So I, I, I totally, uh, totally get the, the vibe. So, um- Yeah... with that said, I, I recorded a very short bio at the outset of this, uh, this interview, but let's start there. If you can give us, like, a, you know, one to two-minute overview of your background- Sure... kind of le- leading up to Infobionic. Yeah, no problem. Yeah, so I've been in and around the business for about 30 years now.
I know I look like I should only have been here for five, but no, uh, just joking. Um, I started out on the clinical side, so I really kind of cut my teeth, and I was running a non-invasive cardiology lab for a hospital down in Florida, and we implemented some first-of-kind technology, and I liked it so much, I ended up going to work for the company who built that. And so that, that was one of the first systems that did cardiac loops digitally versus, uh, putting things on videotape. So that spawned a long track record of doing a lot of firsts, so moving from film to digital, from manual calculations for insulin dosing to, uh, using, uh, advanced mathematics.
I think it was AI before they called it AI. And then, uh, we, uh, got here today where we were the first cloud-based solution that, uh, did cardiac monitoring in the cloud and used deep learning to, uh, assess the signal so that we could improve accuracy. And so, uh, been around for a long time, been through a lot of different positions, a lot of differentologies, but, uh, certainly, I, I grew up-- My mom was a nurse, so I grew up doing home health visits with her. So always have had a altruistic motive behind the scenes. So it's good to be in a place where we are today, especially where we're helping people, uh, you know, improve their health or, or find stuff early enough so that it helps them.
You and me both in terms of, uh, our moms being nurses, right? I think it's, uh- Yeah... a little, little, little bit easier to, um, or a little bit smoother transition to kind of in the into the world of ice, right? It, it- Yeah, yeah... hits home a little bit, little bit different way. So that's cool. I mean, we'll link to, um, your LinkedIn profile and the full write-up on MedSider for those that are listening and wanna learn, learn a little bit more 'cause you've got a pretty storied, pretty storied career, right? Leading up to, uh, up to this point, so it's, it's pretty cool to see. So let's talk a little bit, uh, before we ki- kind of go, go too deep into the interview, let's talk a little bit about, about the, the Momi ARC system, right? Which is, you know, you- your kind of your, your core platform- Mm-hmm... at Infobionic. So give us a sense for maybe what it is and, like, the core kind of problem or, or, or area- Sure...
that you're, you're trying to improve upon. Yeah. So I mean, I maybe just kind of a, a throwback to how the company was founded, right? So a gentleman who's, uh- Founded the first electrophysiology lab in, in New England. Um, you know, when, when monitoring came around, it ultimately got to the point where you thought there just had to be a better way. You had multiple different devices for individual tests. You had different, you know, even fax machines, you get a different fax report, or when it finally went electronic, you had different logins. Very difficult to adjudicate or, you know, try to correct a report after the fact, and he just thought there, there's gotta be a better way to do this.
So the idea was try to get everything onto a single device, single platform, single sign-on, you know, more, more of the kind of the one hand to shake, if you will, versus multiple different vendors. And try to use some semblance of technology to make it more efficient to read because, you know, you can produce over a hundred thousand heartbeats a day. You wear that for ten or twenty or thirty days, you're talking millions of heartbeats. So how can the doctors get to what matters the most, uh, you know, get to the heart of it, uh, pun intended, as fast as possible?
Um, and our job is to find the problem so doctors can intervene or introduce a therapy. So the idea was that we created a device that does really only one kind of monitoring, and based on the CPT code that insurance covers, uh, we would, you know, generate a report that meets the requirements for that. We're able to diagnose arrhythmias for physicians or give them the tools to make the ultimate diagnosis and sign off on that. And we do that pretty quickly, very, very efficiently. We were able to stream the data, you know, off the body directly to the clinicians pretty quickly.
Um, and then, you know, when we first came to market, we could do it faster than everybody else 'cause, you know, it was a new and novel way and allowed doctors to be able to get to the, the treatment and the therapy much faster. And the patients love it because they were like, you know, "I didn't have to wait a month to get my results back." They got them back in twenty-four hours in some point-- in some cases. Or they got a call and said, "Go to the hospital," um, or, uh, you know, nothing happened, and they said, "You're perfectly fine," right? So the patients really accepted the, the idea that this ability to get information in what probably be- you know, became more standard. People were used to having their watches on and things continuously monitoring.
And so, um, yeah, so that's what we do. That's, uh, we're able to get information off the body about your heart, diagnose the arrhythmias, and let the doctors intervene quicker and more accurately than they had historically done. That's a helpful overview, and infobionic.ai is the, uh, is the website. We'll link to it again in the full write-up on MedCity, but it's, it's just as it sounds, infobionic.ai. You can definitely check out the technology in a little bit more detail. But, uh, just as a, as, as a follow-up, you're obviously supplying the hardware, right, that diagnoses these various arrhythmias. Are you also like... Is it, is it the full kinda closed loop system as well?
I mean, you're providing like the, the software that, you know, physicians will use to, you know, to, to see the, the various diagnoses and, you know- It is. To be able to- Yeah. It's, uh, you know, call it, uh, soup to nuts, if you will. Okay. So, uh, what happens is a patient, if they're feeling like they might have some symptoms and, you know, given the prevalence of cardiovascular disease, almost everybody I talk to, if they've not had some issue, they know somebody or somebody that, that's been in their family. But if you're having some kind of symptoms that cause you to call your doctor and, uh, say it's a general practitioner, and the general practitioner says, "Well, that sounds like that might be cardiac.
Let's make a referral to a cardiologist," then you talk to the doctor and, and y- you can do these over the phone now, a virtual, you know, uh, health visit, or you can go see them directly in the office. And if, uh, if the indications are there and it meets the requirements that the insurers require, they'll order the device. So we, we manufacture the device, so the device goes on the patient. We manufacture all the software. We build all the AI internally. All of it's FDA-approved, of course. We're able to then, uh, provide the results to the clinicians, uh, whether those are doctors, uh, you know, general practitioners, nurses, you know, anybody who's caring for that patient.
They make their determination on what the next step should be and, and tends to be a, a really efficient process. So yeah, we do it from A to Z, if you will. Got it. We're recording this in, um, let's call it early Q2 of '25 for those listening may- maybe listening after the fact, right? Six, nine, twelve months down the road. Sure. Uh, give us a sense for where the, where the company's at today, right, in terms of its, uh, kinda life cycle. Yeah, sure. So we started the business. We commercially launched in Q4 of 2016, so we've been in market now just a little over eight years. We've got, uh, hundreds of customers and thousands of devices in the market.
You know, we're generally not specific about how many, but, uh, we've got a, a great footprint. Uh, we were the company that introduced a brand-new model that kinda shaped where the market tends to be today. The fact that we were cloud-based and we could use some AI to get really good results caused a shift in the market. So the good news is today there's, you know, there's really not a bad cardiac monitor, so we feel good about where, where we were, we were able to kinda drive the market. We did introduce a new way of doing things. Typically, a doctor's office or a hospital would outsource the service to a third party.
The third party would manage all the logistics with the device, getting it to and from the patient, and do all the billing for that. And then the doctors would bill for a much smaller component of that, just for writing the prescription. So we introduced a way for the doctors to actually take ownership or control of the devices and do all the work themselves. You know, it used to be that outsourcing was the right way to do it because it was a lot of work. We built a fairly efficient system so that doctors could do that, and they could do the billing themselves. So we were able to shift 100% of the reimbursement back to the physicians, and they were able to provide a high-quality service and, you know, you know, be remunerated for that service that they could provide.
So that shifted the market again and we, you know, we saw a lot of, uh, of the competitors follow suit in terms of the model. But still people outsource it quite a bit. There's a lot of folks who just don't wanna have to deal with it. They don't wanna do that work, and so we, we have that same... You know, we can, we can outsource it. We can take on the full service for, for the customers, or we can supply the devices, and they could do it themselves so. Got it But, uh, been, yeah, been in market for quite some time. Uh, fairly good, uh, you know, footprint in the market, and I think probably one, you know, a, a great way to kind of put a stake in the ground and where we landed is we've collaborated with Mayo Clinic where they use us, um, you know, in all of their facilities, and they're an investor in the company.
So we've put ourselves on the map, I think, in terms of quality and innovation. I, I wanted to circle back around to that, that comment here later on, uh, later in the interview because I think that's- Sure... that, that synergistic, uh, investment, right, is, is the ideal scenario I think for, for a lot of us, right, in the world, in the, in the- Mm-hmm... in the world of startups. Um, but that, that's a, that's a super helpful overview and, um, a- and I guess one other follow-up question when thinking about kind of how, how the landscape has changed, and you mentioned, you know, physicians are now able to bring this sort of this technology, right, in, in-house. Is that the overwhelming majority of, of how your customers are, are adopting, you know, your, your technology?
Is they're-- they, they are in fact bringing it in-house versus kind of out, the, the legacy model of outsourcing? If you look at the market, you know, between hospital systems and then physician practices, when you look at the physician practices that are independent, not hospital-owned, it represents about 25% of the tests that are done in the market, so a relatively small portion. That segment of the market when they're independent and, you know, they're, you know, they're fighting to stay alive and keep their businesses, you know, with, yeah, lots of pressure on profit margins and so forth, and demand for patient continues to go up, but there's a shortage in doctors and physicians.
The ability to own and operate the model, um, works very well in that space. We only see it in the hospital space where, again, about 75% of the tests are generated from about 10% of the hospitals own and operate the devices. Given just the complexity of their environments, um, it's very difficult for them to take on additional services. They're already pretty stressed for resources, so it's just easier for them to continue to outsource it. So I think we, we-- we're seeing a shift on the hospital space and more people taking it on, for example. Mayo Clinic, obviously, as I mentioned, a, a great example of that.
And our hospital-based customer base, you know, grows pretty substantially year over year. So I think in time we'll see it to be a bigger, bigger chunk of that, but I don't think the outsource model will ever go away just because a lot of facilities just don't have the time or the, the resources to do it- Yeah... just given the pressures of how they operate business and how healthcare works. Yeah, m-makes sense. And, and the reason, the reason I, I, I, I kind of wanna-- I wanted to bring that up or at least ask the follow-up question is because I think it's super smart, right? As a, as a, as a s-- you know, I'm gonna call it Infobionic a startup even though, you know, you've got eight years under your belt of, of, of- Yes... of commercial kind of, uh, uh, of being commercial.
But, um, it's super smart to have both options, right? To be able to service, right, that sort of that, that owned market, if you will. Mm-hmm. Right? But yet still be able to kind of offer sort of a full service, you know, sort of, uh, platform to, to hospitals. So I think it's super smart. And then the other thing too is, you know, if you're, if you're listening to this and you're a startup and you're not thinking about like plays that-- where you can almost empower physicians, right? Not only empower them with better technology, but empower them with more of a, you know, a, a better economic model. Mm-hmm. Oftentimes you'll see, you know, very quick adoption, right? In that, in that case, and I think that's really sharp and, you know, you should...
You know, if you're early into your, your, your startup idea, you should be thinking about that, that, that sort of, uh, that sort of landscape and how you're- Yeah, I think the, the key we learned is, is you have to be able to sell it the way the customer wants to buy it. Even if we think that, you know, one, one way is better over the other one, at the end of the day, the customers, you know, that, that adage, customer's always right, however they wanna buy it and own and operate it. But you still need to be able to provide that high level quality of service, the innovation that they're, that they're looking for. And we've found s- all sorts of interesting ways of efficiency, right?
So if you, if you, if you, uh, can remember back when we didn't have cell phones, right? And you would travel all day long and, you know, and work, and you'd get-- at the end of the day, you'd have to catch up on your emails, and it was all this extra time. That still happens in, in this particular ology, and I've heard stories from our customers where their colleagues, uh, they're riding the same train home. They live in the city, and their colleagues at the end of the day are pulling out their ECG reports on the train and, you know, going through and looking at them on paper. Whereas in a model where we're constantly communicating, and they're able to see it, and they get the alerts on their phones as it occurs during the day, no different than you get your emails and you, you deal with all that stuff during the day.
You don't have to wait till the end of the day. So there's a big efficiency gain, and we can do that in either model. And I think to your point, it's like, you know, being thoughtful about, you know, you wanna be able to provide it the way the customers wanna buy, but you also-- regardless of how they buy it, you still wanna provide that value add, those services and efficiency and quality. Yeah, no, no doubt. I mean, we, we have a kind of a similar, a very similar view at, at Fastway, which is the company that I'm, that I'm running. We're, we're working on, on two different energy platforms in the IVL, intravascular lithotripsy space or IVL space. And one of the, the more common questions we get is why, why are you doing both, right?
Well, there's a number of reasons, but one of which it does-- it gives us kinda unique optionality to service a different side of care whose needs are, are, are different. So, um, I like, I like, I like the play. But with that said, again, for everyone listening, Infobionic is the website. Uh, infobionic.ai, I should say, is the website. We'll link to it in the full write-up on Medsider, but again, infobionic.ai if you wanna learn a little bit more about the company and the technology and kind of their, their, their story. Um, so with that said, uh, Stuart, let's go back in time. Learn a little bit more about kind of the, the journey getting up to, you know, uh, kind of early, early twenty-five here. So you mentioned that you've been at the helm, I think, eight years now, is it, right? Or maybe a little bit- Just, yeah, just a little bit over, yeah. Little bit, a little bit over eight, eight years.
Um, I'm sure when you first joined the company, you know, and took on the CEO role, the Momi system didn't, didn't look like it, it is today, right? So or, or, or probably, you know, have made a number of different improvements since then. So when you think about those earlier days in a startup, right? And may-maybe think about even your, your previous startup experience because you've got- Mm-hmm... you've got a lot of sort of swings at the plate. What do you think is most crucial for startup kind of founders, CEOs to think about when they're trying to move quickly through those early development phases, but often have, like, very limited kind of resources and, and, and capital to work with?
Yeah, it's, it's a gr- it's a great question, and I don't think any startup's immune. I mean, not a-- I mean, you, you do get the unicorn, right? Where the market just kind of takes off and, you know. But I, I actually read something very interesting where, um, an interview with a, you know, a, a premier, uh, venture capitalist, and they said, "Yeah, we, we won't hire anybody that's had a successful run on their first run," right? They, they, uh, you know, because they want people who have had to, to, to work for it, right? And go through the mistakes because that's how most of the companies go through it.
And, and it's, it's challenging, it's difficult. You know, it's generally gonna take twice as long, cost twice as much, right [chuckles] than, than, uh, than you ever planned for. You know, so I, I think, you know, for us, you know, w-we experienced all of those things, right? I, I mean, I think the adage that a ship in the harbor is, you know, that's not what it's meant to do. It's meant to be at sea, right? So rough seas make for, make for skillful sailors, and that's what, you know, startups are like. It's there's always something, um, and you know, we certainly had our own headwinds. We brought a novel, uh, model to market. It became an existential threat to all of the existing incumbent inventors in the space because it threatened their model.
So, you know, we had people try to sue us, um, and, you know, spend a lot of money. And so, uh, we ended up ultimately winning on all of those things. But we spent, you know, tens of millions of dollars defending ourselves, you know, only in the, in the end to be right. And looking back, you know, what could be-- what could we have done with tens of millions of dollars on new product, right? So it certainly had, certainly had its effect. You know, but I think the, the, the concept of, of perseverance is in, in, you know, having, you know, staying committed to your cause if, if you know it's the right thing.
I mean, we were clearly able to demonstrate early on that people were willing to purchase and adopt the system. We saw great adoption when it went in, and then we-- once it went in, forty percent of the growth came from the existing customer base, and that still holds true today. So we know it's a good technology. We know that when it goes in, it's nice and sticky, has a lot of value. So that allowed us to say, okay, when the things... You know, when it get-- when the tough got going, you know, we had to get going tough, right? And so but we, we knew that our model was there, and so we persisted. And so we had to find investors, um, that were willing to fight the good fight with us, which is really hard to do.
There's not a lot of investors that wanna get into the fight when you don't know what the outcome's ultimately gonna be, [chuckles] right? So, so that persistence and, and, and, and really having a good team around you, right? So we had a, a really committed team of folks that stayed through the really tough times. And so we were able to persevere, and then we ran into the pandemic also, right? So you kinda get these double whammies. But, you know, along all of the-- all of those, we had, you know, key wins, you know, very, uh, large-scale adoption, um, by, you know, preeminent health systems in the marketplace.
And it always told us that we had the right calculus and, you know, we needed time and effort, you know, to be able to play that out. And so here we are eight years later. You know, are we at the projections that we thought we'd be when we first started out? And, you know, few people ever get to, to the, to... You know, you think you're gonna be a hundred million dollar company in three years. We're well on our way, but, you know, certainly it, you know, it takes time and it takes a lot of effort. But we've crossed all the bridges. Uh, we feel great now. We've got a lot of wind in our sails. The growth is there. We had a phenomenal, you know, record year coming off last year, so, uh, feel, feel good about it.
So I think, you know, the biggest advice is perseverance, making sure you have the right team around you. You know, making sure that your, uh, what it is you're doing is you can continually test and validate it's the right strategy. Otherwise, you need to, you need to pivot. It's constantly testing to pivot or persevere. And we found that we could persevere. Didn't have to do a lot of pivoting. Um, we just had to find the right mix of investors and team to, you know, wanna fight that good fight and, uh, and we've done that, and, uh, now everybody's starting to reap the rewards, and we're pretty pleased that, uh, that we punched through.
So easy, right? Looking back. [both laughing] Yeah. Hindsight twenty/twenty, right? Exactly. Exactly. But j- but joking aside, you mentioned a couple things, right? I mean, perseverance being one of them, and man, so many, so many, uh, founders and CEOs that come on the program do echo that sentiment, right? Like, that's just... That is part of the startup game, right? Um, you're undoubtedly gonna, gonna, uh, encounter fire drills maybe on a daily, [chuckles] maybe on a daily basis- Sure. Yeah... that, that need, need to be addressed. But, um, you know, your, your comment about, you know, a, a ship in the harbor is really-- is meant for sailing. I, I haven't heard that analogy before, but it's a great one.
Kinda reminds me of the similar comment that, uh, Mike Deneen made. I had him on the program maybe a month or two ago. He's running Tioga Medical, which is a-- or Tioga Vascular. Tioga Medical. I can't remember exactly. But anyway, so he's the chief of that company. I don't know if you know Mike, but he mentioned something similar, right? Like, when you're in these early stages, it always feels comfortable to, like, get into a cadaver or get into a study, right? 'Cause you don't, you don't feel like your technology's there yet, or you need to make one more tweak or one more refinement. And, you know, your analogy of, like, "Look, we gotta push it out to the seas at some point," you know what I mean? And- Right. Yeah, yeah, yeah. Yeah, yeah... it, it, it's gonna be, it's gonna be bumpy.
You know, there's gonna be some waves. Yeah. But we, we gotta do it, and that's gonna make us stronger. And so I think that's just a, you know, really, really good, valuable advice. Again, I guess the other thing too that you, you touched on is team and having the right team around you, including investors. Uh, and I, I couldn't agree more. To have investors, even if it means maybe not the most ideal terms, right? But if they're gonna be- Right... around- It's true... right? No, it's very true... and willing, willing to fight alongside you, that can often have much, much more, uh, significant impact, right? Than- Yeah... than the, the best, you know, the best, you know, deal on a, on a, on a term sheet. So I think that's really important for, for those that are considering, uh, considering their next, their next capital raise is don't, you know? Yeah.
I couldn't agree more on the sentiment of sometimes it's not the best terms, but it allows you to continue to, to stay in the game. And if you stay in the game and you're successful, you can always, you can always put new terms in place later, right? Um, you can... Uh, lot, lots of ways to do that, and that's, you know, that's the, the, the gymnastics you can do in venture capital is, you know, it has a pretty wide swath of, of, of creative ways to finance and, and recover, you know, even if you don't have s- you know, such good terms, uh, on, on a particular deal. But it's all about staying in the game, doing whatever it takes to fight, you know, especially when you're committed to your cause. You know it's working. 'Cause we knew people were buying it.
People loved it when it went in. You know, our NPS scores were absolutely fantastic. You know, we had, uh, you know, world-class, you know, commentary from our customers. You know, everybody told us, you know, we, our technology was the best. So we knew we had something, so we never gave up. And so we, we figured out a way to survive and ultimately get in a position where your, your strength, your year-over-year growth's there, the revenue's there, profitability, cash is good, all those things are working. Customers are happy. Now you've got some leverage to go and renegotiate terms. Um, and then, uh, if you can, if you can get to that point, then it's a good position to be in.
Um, and so you're-- I think you're, you're absolutely right about, you know, staying in the game is the key. Yeah, no doubt. [upbeat music] Hey, everyone. Let's take a quick break to talk about Fast Wave Medical, the company I co-founded and lead as CEO. We're developing next-generation intravascular lithotripsy systems, or IVL for short, to tackle complex calcific disease. The IVL market is valued at over ten billion dollars, but there's currently only one major player. In early two thousand twenty-three, we opened up an investment opportunity to our community, and within a month we secured close to ten million dollars.
Then in early '24, we closed an oversubscribed nineteen million dollar round in just a few weeks, bringing the total investment into Fast Wave to over forty million dollars. Corporate interest in the IVL space is growing, too. The nine hundred million dollar acquisition of Bolt Medical by Boston Scientific and then J&J's thirteen billion dollar acquisition of Shockwave Medical signals a lot of attention towards emerging IVL startups like Fast Wave, and we're making some serious progress. Fast Wave recently received its seventh patent for our differentiated laser IVL platform for coronary applications.
On the clinical side, last year we completed the first in-human study of our advanced electric IVL system with some pretty compelling results. Next up in 2025, we have IDE trials planned for both our peripheral and coronary IVL platforms. So if you're interested in investing in the fast-growing IVL market, sign up for our investor wait list at fastwavemedical.com/invest. Again, that's fastwavemedical.com/invest. Now let's get back to the conversation. [upbeat music] I gave this little presentation to, uh, he goes by Zeke, Steve Solinsky in, in Minneapolis. He runs a group called SMMG, I believe is the acronym.
But, um, it-- that, that was like the ma- like the, the overarching theme of the, the, the little talk was like, you know, survive and advance. I think we were at like March Madness, I think, [chuckles] is when I came up. Yeah. [laughs] But it was like, that is like, that's, that's what it is, right? I mean, survive and then advance to the next, the next round or the next phase, right? Uh, um, I guess is probably the better, better way to describe it in, in our world. But, um, on that note, we touched on, on financing already, but you've ra- you know, you've raised-- you've been a part of a, a lot of different, you know, rounds of financing over the years. Obviously- Yeah... those at, at, uh, at InfoBionic as well. When you think back about just everything that you've learned about how to, how to effectively raise capital, you know, are there, are there a few, you know, one or two like really important things that kind of have always stuck with you or maybe that are especially important for other, other CEOs that are a little bit newer to, to the, to the game of fundraising?
Yeah. I mean, and I think one of the, the interesting things that I found was, uh, the creative use of, you know, working with debt, venture debt, right? Non-dilutive capital. You know, there's, there's tricks to should you let the interest pick after a long time, and then if you wait too long, you know, if you can't, if you can't service it, then you're upside down. It makes it really difficult to get out from underneath. So you have to be careful about how you do that. But I, I think there's, there's that. I mean, you know, equity is, is what I would call prime real estate. You wanna be real careful with how you dole that out.
There's probably really good ways to use the mix of both debt and equity to fund certain initiatives. I think if you're getting into positions like we are now, where we can think strategically about deploying capital, not just for growth, you know, R&D and salespeople and things like that, but where we'd look at more strategically on, you know, whether it's M&A or partnerships, things of that nature, you know, that's where, you know, the mix of debt and equity can, can really-- you can play nice together with that. So finding, finding a really good investor that's, uh, willing to work with you on the debt side, we were able to do that and, and we've, we've re-upped, you know, a couple of times with, with the same group just because they've been great partners with us.
When things got tough, they hung in there with us. You know, they were easy to work with, and so that creates some loyalty. And yeah, so I think it's just a matter of, of not being afraid to look at alternative means of financing, um, looking at creative ways. Utilize your-- the, the knowledge of your existing investors 'cause this is what they do for a living. Um, if it needs to get creative, we-- you, you can get creative. And, you know, in today's world, especially for companies, you know, kinda coming up in the business, the idea of partnering with healthcare systems as part of your-- whether it's, you know, with their corporate development venture arms, uh, as well as their research components, being able to capitalize and, and partner and be creative with those groups to bring them into the fold, I think is key.
Because the way, you know, reimbursement and the landscape of how care is being shaped as we go forward, companies like us, when we're a relatively small startup, it's difficult to go and try to negotiate with the United Healthcare and things of that nature. Whereas, you know, a large health system, you know, in the venture arm, you know, they, they have a, a much different, uh, voice in that conversation. Um, and it's, you know, very valuable to have, you know, that side of the equation, the insights that can come with that, along with your investors from, you know, whether it's venture or private equity or family office.
They've all got their own experiences and creativity when you-- and then you kind of put all those things together and mix it up in-into one pot. You know, you can really create some really interesting outcomes that can really grow the company and, and more importantly, move the needle in healthcare and really provide some value. No doubt. Uh, a-and you mentioned that earlier, your relationship with, with Mayo. I'm not sure if that's, if that's the only healthcare system that, that's involved kind of at the sort of the cap table level, if you will. But I, I couldn't agree more with proactively looking for that type of investment. Mm-hmm. It's so synergistic in so many different ways. You mentioned one of them, right?
Just like, how can we get an intro to United Healthcare or name your big payer, right? Right. I mean, if you're, if you're just a small fledgling startup, it's-- I mean, you can do it, but it's just gonna take that much longer, that much more time, gonna be- Exactly... you know, it's g- that much more distraction away from like, you know, your core operational exercises. Where if an investor at maybe Mayo take, uh- can provide that intro- Sure... and it's like, boom, makes all the difference in the world. I mean- Yeah, yeah. Yep Yeah, so- You're, you're spot on. Yeah, absolutely. Yeah. Let's, let's pretend you're at a, at a, at a new company and you had, and you had raised, you know, another round of capital. Would you specifically look for that type of investment, sort of that, that smart money, if you will then, I presume? Yeah. Um, I mean, I, I-- short answer is yes. Uh, but I think it also d- kinda depends, right?
It depends on what you're, you know, what product m- and, you know, what kind of market fit you're, you're going after, right? So one of the, you know, one of the key advantages, and, and, and we've published this, it's on our website press releases, was to work collaboratively with Mayo Clinic to help facilitate bringing some of their research-based, what they call, uh, AI ECG, bring it to market. And so by working with them through what we established called a know-how agreement, which is effectively a fancy term for a research agreement where we can capitalize on, on their, their knowledge and help develop new products, do studies with them, and then utilize their assets and resources to perform those very, very quickly.
We are in the throes of getting ready to bring a, a, a new AI model to market that's d- you know, designed to detect late, you know, latent disease, so different than workflow efficiency where you're trying to, you know, make, make things easier for people to do. This is actually looking deep inside of your ECG for kinda hidden secrets, if you will. And, you know, the idea that, you know, we We needed to find some converging comorbidities or tests that needed to be related to the ECG.
It was very easy for us to look across all of the studies that we'd done to look for some of these converging lines of other tests that were within some, you know, some timeframe that had both positive and negative so that we could put together a very sizable cohort so that we could train the data and submit to the FDA and, and, you know, have a very defensible capability. So to answer your question is, if I'm in that space and I've got that kind of product where I could capitalize on some of the, the...
You know, 'cause there's a lot of academics that have great AI labs, right, in today's world on many, many fronts, whether it's lung or cancer or, you know, they need a conduit to get it to market, right? So if you can, if you can align yourself there to be the commercial distribution, um, but capitalize on the, the prowess that they have, you know, with their research and some of the experience that they may or may not have with the regulatory bodies and the insurance providers for getting codes established. You know, those are all hard- things that are really hard to do for a startup if you've never done it before.
Whereas the, the big systems with, with venture arms, uh, academic, you know, health systems, they've got a lot of experience there. So the answer is yes, but I think it kind of depends on what you're bringing to market. Yeah. It's all, all good stuff. Let's talk a little bit about your clin reg roadmap, right? And, and feel free to kind of work in kind of your, your thoughts on how, how, you know, coming to market, right, you're bringing, you know, sort of a new, a new commercial model a-as well. So I'm not sure exactly how that impacted kind of like your, your thoughts around clin reg. But I think you announced the next gen, uh, Momi ARK received- Mm-hmm... 510k clearance last year. I think some in 2024.
Correct. Yeah. Correct. Yeah. Yeah. That's right. Yeah. So over the years, when you think about how to, how to effectively map out, right, that, that roadmap, what would you maybe tell y- the younger version of yourself? Well, I tell, I tell my old version too, right? But, uh, uh, yeah. So, you know, it's, um, it, it, it takes time, right? The whole regulatory strategy takes time. I think the, I think the FDA is working really hard to become more efficient, you know, with the, you know, kind of new electronic ways to submit all the goings-on recently. It's, it's, you know, all about trying to create as much efficiency as possible. You know, we've got one in submission right now. We're right in the middle of that.
We, we expect approvals on that in the not-too-distant future. But we've got probably at least four or five more in terms of, of submissions. I think, you know, what I would tell my s- younger self now is, is learn how to communicate early and often directly with the FDA. You know, get to know them. Let them get to know who you are, what it is you're actually doing in the market. You're not just another K number that they're approving. You know, there's actually real, you know, like the, the benefit that we bring is, you know, we're detecting early disease, latent disease in your ECG, and that's a lot of what our submissions are gonna be centered around, and that has a huge impact to the reduction in cost of healthcare if we can find a lot of this stuff early.
So if the FDA can understand that and get to know us and, you know, we, we get to know them better of what they expect in terms of the submissions and all of the new guidelines that they've got with AI, if we do our studies correctly and we're buttoned up the way that we should be and we're planning appropriately. I liken it to, uh, uh, Star- you know, a long time ago, Starbucks, uh, you know, made a rule that their baristas couldn't make more than two drinks at a time. So everybody got in a big uproar because it slowed them down, right? But they had to slow down to speed up, right? Because they, they had too many mistakes.
So I kind of liken it to that right now with, with the, what we're trying to do with the FDA is, is slow down. You know, let's understand precisely how we-- these need to, these need to be handled, how they need to be submitted. Slow down, let them understand what we're trying to accomplish so they get to know us, so that each and every submission gets a little bit better, a little bit faster. I think that only does the market better. It'll certainly, will certainly serve healthcare a lot better. But, you know, I think that that idea from a clin reg strategy is it has to be almost the central part of your strategy because you can build great products, but if you don't have the right clin reg strategy, then it, it's just gonna take you that much longer to get it to market.
Um, and so, uh, you know, we're-- we learned that. We had to kind of slow down to speed up, and I think we're in a position now where we figured that out. We've got good consultants, we've got the right resources, and we're making sure we understand all the rules that we need to play by so that when we do submit, the submissions are high quality. It's such a good point and, and a good reminder quite honestly for my, for myself is that at the end of the day, like it, it's, it's people on the other side of the, the, the table, right? 'Cause we often think about, you know, this idea of communicating early and often, right, to FDA. It's like, "Oh, well, we'll do a QSub." Well, yeah, yeah, but it's more than that, right? Like- Right...
make an, make a concerted effort, right, to, you know, to get to know them, but also allow them to get to know you, right? 'Cause every follow-on, you know, whether it's a QSub or an IDE submission or a 510k submission, whatever, like there's just that much more trust built up, right? Um- Exactly. Yeah. Exactly. Yeah. And, and it's undoubtedly gonna help if you think about just, you know, normal, normal human behavior, right? [chuckles] Yeah. Yeah. The more you get to know someone, uh, typically- Yeah. You build trust, right? Yeah. It's, yeah. I mean, it's, um, I hate to boil it down to this, but you know, people buy from people for two reasons: They like you, and they trust you. Mm-hmm. So if you can establish both of those, then it helps. Yeah.
No doubt. Let's transition to, to the topic of kind of commercialization 'cause I know you've got a lot of experience both at- Mm-hmm... startups and, and large strategics as well. When you think about wh-whether it's like the kind of the unique partnerships, right, that you've built out with, with Meia, with I think HBox is another one that you, you announced- Mm-hmm... you know, uh, in, in the, in the fairly, uh, recent past. Anyway, just kind of overarching thoughts about, you know, commercialization especially, especially with, you know, the kind of the novel model, right, that you, you, you did roll- Mm-hmm... out with initially. You know, a, a really kind of a, a few key things or mistakes, right, that you've learned from, you know, o- over the years that you think are especially helpful, you know, as you think about continuing to commercialize, uh- Yeah.
Great, great question. Yeah. Boy, I tell you, this one was a big learning. I had kind of hung my hat on, you know, a core competency of, you know, learning how to build pipelines and think about pipeline waterfalls and, you know, learning to really measure the stages of how long deals take and how long they sit in certain stages, and being able to get really granular to say that, "Okay, by April, I need to have X number at this stage in my pipeline in order to hit this number. What's my close ratio, you know, at the end of the year? How much do I need to go into the next year with?" All the timing and all that kind of good stuff. We got pretty good at demand gen over the course of the years.
You know, telemarketing was You know, used to work, um, and threw it all out the window when I got here. None of it worked. Completely different. Um, it was like we were just knocking on doors where just... And, and the houses were empty, right? Just nobody there. So the market completely has changed, I would say, at least in the cardiovascular service line, how it buys. And, you know, the market that we're in, it's 100% penetrated. I heard a doctor say once, "I can't swing a dead cat and not hit 10 cardiac reps in my office."
So it's a really crowded space, so how do you rise above and get attention, right? And so when you don't have a product problem but you have a channel problem, you have to diversify. You gotta really think about, you know, how can you be where the customer's making a decision? And so, you know, we, we tried a lot of different methods, and where we, we ultimately landed was we knew that relationships in this particular space became really important because in the, in the pacemaker and the defibrillator and the implantable loop recorder side of the business, you've got reps who are at the, at the tableside with electrophysiologists for decades building those relationships, right?
So those people go in the employee door. They don't go in the front door. But in a... So in a hospital, you can't just go in the front door. It doesn't work anymore. You have to be registered, or you have to be part of the system, or you have to be on contract with the hospital. You know, there's, there's no such thing as cold calling on a hospital anymore. Or, or if you can, it-- you gotta be pretty creative. So you, you have to figure out how to get in on the employee door, right? Um, and so figuring that out is something that took us a, a while to do, and so we figured out how to build out, you know, some large independent rep channels that had those relationships, right, that, uh, you know, kind of walk you in, in the front door.
Now granted, you know, they're working for big companies, and they, they may not have more than three to five customers that they ever managed across, you know, a, a 20-year career. So if you're, you know, utilizing a channel like that, you have to know you need a lot of them because they only cover, you know, a very, very [chuckles] small part of the market. And after, you know, they're not gonna convert, you know, all 100% of them, so you might get one or two out of that, out of, out of there. So you have to, you have to have a lot of that. So that, that's a big effort, big challenge. It turns out if you pay the right attention to that, that can work. Now, you flip it to the independent cardiology space, different story. The cold calling, the, the...
or the telemarketing doesn't quite work so well, so what we... how we f- how we figured that out was you just gotta send human beings into the office, and you've gotta have a really good service. And so if you can understand what, you know, the, the failings are of your competitors without talking bad about your competitors, but go in and talk about how you're better in those key areas, it doesn't take much to switch because in that, when I talked at the top of the, the, the call, that outsourced model, it's easy to replace because all the doctors are doing is writing a prescription to a service.
So you could easily walk in and replace that because there's-- you're not uninstalling hardware. There's no EMR integrations that you have to worry about, right? So the switching costs are low. Becomes a lot easier. So you just need, you know, people who have the, the intestinal fortitude and the mental fortitude to be able to walk in, cold call on somebody and, and, you know, knowing that they're already using likely two or three of your other, of your other competitors. And, you know, your, your, your job is to get, to get a foothold in there, so you get a few devices and then, then you work upstream.
So I think gone are the days of having, you know, a single methodology for sales channel. I think it's a multi-pronged approach, some direct, some independents, uh, other distribution, uh, resellers. Um, you know, we've, we work with the Mayo Clinic. They're actually a distributor of our product. They started up and went to market as an outsourced service provider, and, and, uh, we're, we're their distribution channel for it. So I mean, we, we, we definitely got very creative across the board. That's probably the, the biggest thing that stands out, like hearing you kind of riff on your experience, you know, commercializing at InfoBionic is just this idea of just taking multiple swings, right?
'Cause you can plan- Yeah... and strategize all day long for weeks and months and even quarters, but until you kind of get hit in the face, you know? Uh, what's that Mike Tyson- Yeah, yeah. [laughs]... quote? It's like Mike Tyson where you're like- Everybody's a fighter till they get punched in the face, right? Yeah, yeah. Mike Tyson, yeah, yeah. But, but there's a lot of truth to that. It's true. Yeah, yeah. And, and, and- It's, it's true... you know, and so, um, kind of similar to what we discussed earlier, right? At some point you gotta, gotta, you know, you know, the ship's gotta, gotta get out of the dock, right, and start- Yeah... start sailing and, you know. And, uh, so we, we, we tried everything, and, uh, you know, I think we, um, we landed on a particular, uh, I'm not-- I won't give it away, but we, we've got a particular persona or role that we've found that in my 30 years I never ever, ever would have guessed that would have worked.
We did. We stumbled into it, and it works really well. So I'm not gonna give up the secret, but, but it took a lot of, it took a lot of gyrations to get there, for sure. Yeah. I mean, that, that's a, that's a great example, right, of like just, you know, try it a different... You know, it was probably, probably highly unlikely that you would have kind of tapped into this, this particular like role or this channel, right, without trying- Yeah... different things, so. Yeah, and I'm, and I'm not so sure it would work anywhere else on any other model, but it just hap- Yeah... we, we just happened to turn the dial on the combination lock, and the lock unlocked, and we were like, "Hey, we, we just figured this out," so. [laughs] It works, it works. Yeah.
So we're, uh, we're-- that's where, that's where, uh, that's where we're putting a lot of our growth money is, is into that, so. Oh, yeah. That's awesome. Um, I wanna get to the... leave a little bit of time for the rapid-fire portion of this interview, but I guess la- last question I wanna, uh, discuss is, um, is when you think about M&A, right, M&A activity, whether on the kind of the sell side as you're, you know, trying to sell a startup to a, to a larger strategic or even thinking about the, the, the integration process 'cause if the in- integration doesn't go well, that's, you know, likely not gonna, not gonna lead to, you know, a lot of, a lot of long-term success on both sides of the table. So, you know, I know, uh, you were part of Capsule Tech, right, which I think initially sold to, to Qualcomm, but then- That's right...
if I remember correctly, Qualcomm was then integrated into Philips or sold to Philips. I can't remember exactly how that went, but- Uh, Francisco Partners bought it from Qualcomm and then sold it to Philips. Yeah. Okay. So it bounced around a little bit. So when you- Yes... I guess when, when you think about just M&A in general and how to, how to e-effectively either, either best, best position your startup for an M&A or, or just- Sure... the actual M&A process itself and any, you know, the integration. Any key lessons learned kind of in, in, over the past few- Yeah... years or so? I mean, I think, you know, a couple of the, the, the, you know, kind of what I picked up and I've, I've worked for some private equity, family office, venture capitalists, right? So, um, all just great, smart people.
They all have kind of their formulas, what they look for. But I think probably pretty consistently is if you can build a core business that, that has good solid growth year over year, that's kind of like the number one metric. Your revenue is growing year over year, or you have at least north of 30%. If you can get 40, 50%, you know, uh, it's great. There's all sorts of benchmarks that say in the first three years you should be over 100% growth year over year and then, you know, should settle in, you know, out on years four and five around the 60% kind of stuff. If you're in the 10-year range, you know, and, and you're growing and your, your numbers are bigger, you're not in the land of small numbers anymore, so your percentage growth rates are gonna change.
But regardless of, of where you are in the cycle, as long as you've got good solid year over year revenue growth and your profitability is commensurate or growing, you know, I think, you know, in, in a lot of cases for startups, the profitability is less important than the year over year growth. If you can do both, the rule of 40, 40% year, uh, year over year growth and 40%, uh, margin or EBITDA, you're in a pretty good, you know, you're in a pretty good, uh, place. But I think what, what I learned though was, um, not just the year over year growth, but can you create a new product and a new addressable market for something that's highly synergistic for a particular segment of the market?
So we're in monitoring, cardiac monitoring, right? So we, we know from a strategic perspective all the players that might be interested in, you know, somebody like us. Um, and there's a handful that, you know, you know, maybe not necessarily wouldn't you think would make sense, but might make sense. But, you know, but we're, you know, we're focused on all the things that would, you know, drive the valuation into kind of the A-rated valuation. But if we've got a brand-new market where we've, we've been able to develop a product, it's in market, we got a handful of customers paying for it, and it shows a sizable growth, now you give somebody a reason to give you a, you know, if you're a, if you're, if you're an A-rated financials, you get an A-plus valuation just because you've given them some, a, a big growth engine on top of a really solid business.
So, so that's really our formula is, is to do that. We wanna build a, you know, good solid core business, but at the same time we know if we can hand off something that's unique, um, and another game changer, um, for the, you know, to carry monitoring into the next, you know, 20 years, then that would help. And we did a little bit of something like that at Capsule in fact. Um, and that's kind of what led to some of their trajectories. So, um, I know the formula works, and so that's, uh, what we're focused on is, uh, doing here as well. Yeah. I, I was literally just listening to this podcast, I think yesterday, and, uh, the guest was talking about trend surface area, and I was like, trend surface area. That's kind of...
It seems kind of like cliché, like something a VC would say. Like I'm looking- [laughs]... He wasn't a VC. He was an operator. Um, really smart operator. But, uh- Yeah... but it, it was a really cool concept 'cause he's like, "Well, I've got..." He's, he was explaining his, his buddy that just looks at trends and, and I think that's, that's counterintuitive because it's like, well, if, if it's a trend, it's not here to stay, right? How can, how can that be su-sustainable? He's like, "No, I look for trends with large surface areas," meaning there's stickiness. It's not gonna go away in a year. Sure. It's gonna be... It's, it's got a five to seven-year run, and it, it kind of reminded me of what you just mentioned, right? Look, look for those. Like you've got your core business, right? But if there's like an adjacent kind of space, right? Yes. That you think is trending that could really drive, you know, valuation or something else, like that's, that's, uh- Yeah... you know, beware.
Be, be proactive and kind of think- Yeah, yeah. We're, um, yeah, we're-- that's exactly what we're doing. In fact, we, in fact, Mayo published an article on, uh, what, what's called a tiered monitoring strategy. And so we, uh, we put a stake on the ground and, and validated that that surface area won't just trend. It's, uh, we think it'll be the, you know, kind of the next wave in terms of, of monitoring just because of the way healthcare is behaving today, so. Yeah. Yeah. That's cool. It's tough. Let's spend the last five minutes just talking about burning through some of these rapid-fire questions. Sure. Um, feel free to expand if you want a little bit, but, uh, uh, they're meant to be, uh, rapid-fire nature.
So- Okay... when you think about, uh, Infobionic, take us a year out, right? So take us to mid '26. You know, what are, what are you most excited about? Probably most excited that we'll, we'll have, uh, a, a couple, you know, we'll have a new approval on an FDA this year. Um, that puts us into this, uh, what we call a modular or flexible monitoring platform. So we, we've kind of built the, the monitoring device itself to pop out of a sensor and pop into another sensor. When we, we get this approval this year, that lays tracks for, uh, a whole bunch of stuff for us next year, and that really creates this, uh, it'll build on that tiered monitoring thing that, uh, Mayo's published about.
So that's probably what we're, we're most excited about. Taking advantage of that, that, uh, trend surface area, I see. [laughs] Exactly. Yeah. Yeah. Actually executing against it. That's a good example. Yeah, exactly. Yeah, yeah. Um, uh, all right. Take, uh, eight years ago, took on the CEO role of the company. Is there like one surprising thing that's kind of s-stood out to you over the, over the alm-almost nearly decade you've been at the helm? You know, the thing that surprises me the most is we still have investors in the cap table from day one. Hmm. And they believed in the cause, right? They knew that, that we really had something here in terms of changing the way that monitoring would be, and I think that surprised me the most because I expected things to change and people to lose belief or, or not, you know, uh, not stick around so long.
But they've just continued to hang in, um, and it's been really impressive to see everybody hang in like that. So we've got some, we just got, we have great consults around the table, and that, that's probably surprised me the most is that people have hung in that long. Uh, that's a really good metric though. I mean, to have that, for that, for that long- Yeah... of a time period, you'd expect some of those early investors to be g- you know, washed out or recapped or something like that. Yeah. Yeah, yeah. But it's a really good thing to think about, you know, how, what, what's the tenure of my, of my investors, right? Have they re-upped, you know, each and every time? That's, that's, uh, that's pretty cool. Yeah. All right. Uh, let's, let's see. You know, let's, let's presume, you know, you just maybe gave a talk at a, you know, a small, you know, med tech entrepreneur- entrepreneurial kind of event or something like that, and you wanted to leave, you know, all the entrepreneurs in the room with like one, one single thing that they need, need to really, you know, u-understand, you know, to best position their, their startup for success, what would, what would that be?
Well, I, I, I used to say a-a mentor, right? But now there's AI, so [laughs] it's- [laughs]... which is a great mentor, by the way. Chat, Perplexity, GPT. No, no, but I, I, uh, hands down, um, I do mentoring on the side, um, but I've, I've got ex-CEOs that are good friends. I've had paid mentors, you know, just consultants, right? But u-unequivocally, I mean, uh, you know, the-- somebody told me what-- when I first got into my first CEO role, and he's like, "Look, it's lonely at the top, right? Find somebody you can talk to, 'cause you can't really talk to your board, right, about some issue you're having, 'cause they'll think you're weak." Yeah, that type of thing.
So hands down, unequivocally, find somebody, been there, done that, that you can bounce your ideas off of, uh, you know, have a mentor. Without question, has been probably the, the thing that's helped me the most get through the really tough times even. Yeah. Yeah. Good stuff. All right, last question. Take us back to maybe your mid to late 20s. Is there anything you'd whisper in the, the younger, the younger Stuart's ears at that, at that point in time? Gosh, you know, um, don't take it so serious sometimes. [laughs] Yeah. Um, it's, uh, you know, it's, uh... Y-you get caught up into, sometimes in-into the current challenge that you're having, and- Mm... it can be pretty stressful, right?
Um, and so I've always, uh, cared deeply about stuff, um, but there pr- there were probably a number of times that I didn't have to spend so much energy being concerned about it, so, 'cause a lot of things, with persistence and perseverance, um, things just kind of take care of themselves. Yeah, such good advice. Yeah. Uh, and I, I would echo the same, the same sentiment, right? Um, it's one of the things I, I try to laugh a lot more, right? 'Cause it's like- Yeah, yeah. It's- [laughs] I mean, it's a g- it's a really good question. Yeah. Yeah. Yeah, it's, uh- Yeah. Good... I hadn't really thought about it, but it's a good question. Good, good way to wrap up the, uh, the, the discussion.
So, um, again, for everyone listening, infobionic.ai is the website. Highly encourage everyone to, to check, uh, check, check out the technology and the company in m- in more detail. We'll link to it in the full writeup on, on MedSider. If you're new to MedSider, those write-ups are almost just a, it's a, it's a, a longer form kind of version of this interview, right? If you don't have a chance to, to listen to the whole thing, you can kind of read, read, read that separately. So, um, Stuart, I'll have you hold on the line, but thanks again for coming on the program. Really, really appreciate it. Oh, great to be here. Thanks for having me. Really appreciate it. All right. For everyone listening, thanks as always for your attention. Until the next episode of MedSider Goes Live, everyone, uh, take care. [upbeat music] Hey, it's Scott again. One quick thing before you go.
You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups. But here's the thing, I'd be super grateful if you could help me reach even more ambitious doers who share our passion. So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with MedSider, please take a moment to leave us a review. It's super easy. Just open your Apple Podcasts app or the podcasts app of your choice, search for our show, and scroll down to the ratings and review section. Leave your honest thoughts and hit that five-star rating if you think we're worthy. Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today.
As always, thanks for being a part of our journey and for helping MedSider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews. Stay tuned for another informative episode coming at you soon. [upbeat music]
In this episode of SNL, we sat down with (https://www.linkedin.com/in/lorne-lucree-mba-3585942/)Lorne Lucree (https://www.linkedin.com/in/lorne-lucree-mba-3585942/), the founder and CEO of...
In this episode of SNL, we sat down with Marcus Mounir Hanana (https://www.linkedin.com/in/mmhanana/), CEO of (https://www.pantherls.com/)Panther Life Sciences (https://www.pantherls.com/). Panther is developing...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/brian-le-gette-8956252/)Brian Le Gette (https://www.linkedin.com/in/brian-le-gette-8956252/), co-founder and CEO of (https://ammortal.com/)Ammortal...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/tommoss/)Tom Moss (https://www.linkedin.com/in/tommoss/), co-founder and CEO of (https://signalring.com/)Vital Signals (https://signalring.com/),...
In this episode of SNL, we sat down with Dr. Dustin Freckleton (https://www.linkedin.com/in/dustinfreckleton/), founder and CEO of (https://happysleep.com/)Happy Health (https://happysleep.com/). Happy Health delivers...